Conclusion-Recommendation: Thromboprophylaxis should be regarded as a clinically beneficial and low bleeding risk intervention for most hospitalized patients with COVID-19. Detailed individualized bleeding risk assessment should be conducted, especially in cases where increased dosages are considered.